 |
市场调查报告书
商品编码
1638825
2024 - 2032 年小瓶市场机会、成长动力、产业趋势分析与预测Vials Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年，全球小瓶市场达到 122 亿美元，预计 2024 年至 2032 年复合年增长率为 9.1%。 。这些容器在维持药物的无菌性和稳定性方面发挥着至关重要的作用，特别是在医疗保健环境中。小瓶通常用于包装疫苗、注射和生物製剂，有单剂量和多剂量两种形式。它们用橡胶塞或盖子密封，以防止在给药前污染。
该市场的成长主要是由药品需求不断增长推动的，特别是注射药物和生物製剂，它们需要高品质的小瓶来保持药物的稳定性和安全性。慢性病的增加以及对全球疫苗接种运动的日益重视，大大增加了用于储存和分发疫苗的小瓶的使用。此外，小瓶模型的持续技术发展，例如改进的玻璃配方和防篡改类型，增强了它们的吸引力并有助于市场成长。
市场依准备度分为即用型（RTU）和即用型（RTS）小瓶。 RTU 细分市场目前占据市场主导地位，预计在预测期内复合年增长率为 9.4%。 RTU 小瓶配有预先计量的药物剂量，减少了进一步准备的需要，并最大限度地降低了污染风险。此功能在效率和精度至关重要的临床环境中特别有用。 RTU 西林瓶无需灭菌和填充，从而简化了药品製造流程，从而降低了劳动力和营运成本，同时优化了生产效率。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 122 亿美元 |
| 预测值 | 265 亿美元 |
| 复合年增长率 | 9.1% |
从应用来看，市场分为小分子、生物製剂和诊断。由于越来越多地使用生物疗法来治疗自体免疫疾病等慢性病，生物製剂领域在 2023 年占据最大份额，达到 48.6%。由于生物製剂源自生物体，因此需要专门的包装来保持其稳定性和功效，这使得小瓶成为其分销的重要组成部分。生物相似药的可用性不断增加，为患者提供了更多的治疗选择，进一步支持了该细分市场的成长。
美国在北美小瓶市场中占据主导地位，预计到2023 年将继续引领市场，复合年增长率预计为8.8%。解决方案产生了很高的需求。对药物开发的大量投资，特别是在生物製品和个人化医疗方面，强调需要满足严格监管标准的专用药瓶，同时确保药物的稳定性和安全性。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 慢性病和老年人口增加
- 生物製剂和生物相似药的兴起
- 玻璃技术的进步
- 将製造外包给 CDMO 的趋势增加
- 产业陷阱与挑战
- 严格的监管要求
- 获得替代药物输送方法
- 成长动力
- 成长潜力分析
- 监管环境
- 未来市场趋势
- 波特的分析
- PESTEL分析
第 4 章：竞争格局
- 介绍
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按准备情况，2021 - 2032 年
- 主要趋势
- 即用型 (RTU)
- 准备灭菌 (RTS)
第 6 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 小分子
- 生物製剂
- 诊断
第 7 章：市场估计与预测：按材料划分，2021 - 2032 年
- 主要趋势
- 玻璃
- 聚合物
- 杂交种
第 8 章：市场估计与预测：按规模，2021 - 2032
- 主要趋势
- <1毫升
- 1毫升 - 2毫升
- 3毫升 - 5毫升
- 6 毫升 - 10 毫升
- 10 - 20 毫升
- 20 - 30 毫升
- >30 毫升
第 9 章：市场估计与预测：按最终用途，2021 - 2032 年
- 主要趋势
- 医院和诊所
- 製药和生物技术公司
- 合约开发与製造组织 (CDMO)
- 诊断实验室
- 其他最终用户
第 10 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
第 11 章：公司简介
- Amcor
- Arab Pharmaceutical Glass
- Corning
- Daikyo Seiko
- DWK Life Sciences
- Gerresheimer AG
- KISHORE GROUP
- Mitsubishi Gas Chemical Company
- Nipro
- Pacific Vial Manufacturing
- SCHOTT Pharma (SCHOTT Group)
- SGD Pharma
- Shandong Province Medicinal Glass
- SHIOTANI GLASS
- Stevanato Group
- West Pharmaceutical Services
- Wuxi NEST Biotechnology
The Global Vials Market reached USD 12.2 billion in 2023 and is projected to expand at a CAGR of 9.1% from 2024 to 2032. Vials are small, sealed containers made from glass or plastic, primarily used for storing liquids, powders, or freeze-dried medications. These containers play a crucial role in maintaining the sterility and stability of drugs, particularly in healthcare environments. Vials are commonly used to package vaccines, injectables, and biologics, and they come in both single-use and multi-dose formats. They are sealed with rubber stoppers or caps to prevent contamination before the medication is administered.
The market's growth is largely driven by the increasing demand for pharmaceuticals, particularly injectable drugs and biologics, which require high-quality vials to maintain drug stability and safety. The rise in chronic diseases and the growing emphasis on global vaccination campaigns have significantly boosted the use of vials for storing and distributing vaccines. Additionally, ongoing technological developments in vial models, such as improved glass formulations and tamper-proof type, enhance their appeal and contribute to market growth.
The market is categorized based on preparation into ready-to-use (RTU) and ready-to-sterilize (RTS) vials. The RTU segment currently dominates the market and is expected to grow at a CAGR of 9.4% during the forecast period. RTU vials come with pre-measured doses of medication, reducing the need for further preparation and minimizing the risk of contamination. This feature is particularly beneficial in clinical settings, where efficiency and precision are critical. RTU vials streamline pharmaceutical manufacturing processes by eliminating the need for sterilization and filling, thus reducing labor and operational costs while optimizing production efficiency.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $12.2 Billion |
| Forecast Value | $26.5 Billion |
| CAGR | 9.1% |
In terms of application, the market is divided into small molecules, biologics, and diagnostics. The biologics segment held the largest share of 48.6% in 2023, driven by the increasing use of biologic therapies to treat chronic conditions, such as autoimmune diseases. As biologics are derived from living organisms, they require specialized packaging to preserve their stability and efficacy, making vials an essential component of their distribution. This segment's growth is further supported by the increasing availability of biosimilars, providing more treatment options for patients.
The U.S. dominates the North American vials market and is expected to continue leading the market with a projected CAGR of 8.8% in 2023. This dominance can be attributed to the country's strong pharmaceutical and biotechnology sectors, which create a high demand for advanced packaging solutions. Significant investments in drug development, particularly in biologics and personalized medicine, emphasize the need for specialized vials that meet stringent regulatory standards while ensuring drug stability and safety.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising chronic diseases and geriatric population
- 3.2.1.2 Rise in biologics and biosimilars
- 3.2.1.3 Advancements in glass technology
- 3.2.1.4 Increased trend of outsourcing manufacturing to CDMOs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory requirements
- 3.2.2.2 Access to alternative drug delivery methods
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Preparation, 2021 - 2032 ($ Mn and Units)
- 5.1 Key trends
- 5.2 Ready To Use (RTU)
- 5.3 Ready To Sterilize (RTS)
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn and Units)
- 6.1 Key trends
- 6.2 Small molecules
- 6.3 Biologics
- 6.4 Diagnostics
Chapter 7 Market Estimates and Forecast, By Material, 2021 - 2032 ($ Mn and Units)
- 7.1 Key trends
- 7.2 Glass
- 7.3 Polymer
- 7.4 Hybrid
Chapter 8 Market Estimates and Forecast, By Size, 2021 - 2032 ($ Mn and Units)
- 8.1 Key trends
- 8.2 <1 ml
- 8.3 1 ml - 2 ml
- 8.4 3 ml - 5 ml
- 8.5 6 ml - 10 ml
- 8.6 10 - 20 ml
- 8.7 20 - 30 ml
- 8.8 >30 ml
Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn and Units)
- 9.1 Key trends
- 9.2 Hospitals & clinics
- 9.3 Pharma & biotech companies
- 9.4 Contract Development And Manufacturing Organizations (CDMOs)
- 9.5 Diagnostic laboratories
- 9.6 Other end users
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn and Units)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
Chapter 11 Company Profiles
- 11.1 Amcor
- 11.2 Arab Pharmaceutical Glass
- 11.3 Corning
- 11.4 Daikyo Seiko
- 11.5 DWK Life Sciences
- 11.6 Gerresheimer AG
- 11.7 KISHORE GROUP
- 11.8 Mitsubishi Gas Chemical Company
- 11.9 Nipro
- 11.10 Pacific Vial Manufacturing
- 11.11 SCHOTT Pharma (SCHOTT Group)
- 11.12 SGD Pharma
- 11.13 Shandong Province Medicinal Glass
- 11.14 SHIOTANI GLASS
- 11.15 Stevanato Group
- 11.16 West Pharmaceutical Services
- 11.17 Wuxi NEST Biotechnology
